The Premenstrual Spectrum: A Biopsychosocial Redefinition and the Imperative for Personalized, Staged Management

Authors

DOI:

https://doi.org/10.54536/ajmhc.v1i1.6652

Keywords:

Allopregnanolone, Biopsychosocial Model, GABA, Premenstrual Dysphoric Disorder, Selective Progesterone Receptor Modulators, Staged Management

Abstract

Premenstrual Syndrome (PMS) and its severe variant, Premenstrual Dysphoric Disorder (PMDD), represent a cyclical neuroendocrine-psychiatric phenomenon affecting a significant proportion of individuals of reproductive age. Despite its prevalence, management remains fragmented, often oscillating between minimalization and over-medicalization. This paper proposes a paradigm shift from a symptom-checklist model to a “Premenstrual Spectrum” model, integrating recent neurobiological findings with psychosocial determinants. It advocates for a staged, personalized management algorithm tailored to symptom severity, functional impairment, and patient preference. A narrative review was conducted synthesizing literature from October 2023 to November 2025, focusing on randomized controlled trials, systematic reviews, and novel pathophysiological studies. Emerging evidence solidifies the role of allopregnanolone sensitivity, GABAergic modulation, and genetic polymorphisms (e.g., ESR1, BDNF) in etiology. Low-grade inflammation and gut-brain axis dysregulation are identified as potentiating factors. Non-hormonal interventions, particularly selective progesterone receptor modulators (SPRMs) and novel GABA-A receptor modulators, show significant promise. Cognitive-behavioral therapy (CBT) and mindfulness-based interventions demonstrate robust efficacy for mood and cognitive symptoms. PMS/PMDD is a legitimate, multifactorial condition requiring a nuanced clinical approach. A biopsychosocial framework combined with a step-care treatment model—ranging from lifestyle and behavioral interventions to targeted pharmacological therapy—optimizes outcomes. Future research must prioritize non-hormonal targets and culturally adapted management tools.

Downloads

Download data is not yet available.

Author Biography

  • Aqsa Akram, Department: Department of Obstetrics & Gynaecology, Fatima Memorial Hospital, Lahore, Pakistan

    My name is Dr. Aqsa Akram, and I am a triple-board–certified Obstetrician and Gynaecologist (MRCOG-UK, FACOG-USA, FCPS-Pakistan) with a strong academic foundation built on 14 Gold Medals during my MBBS and more than five years of progressive clinical experience. I currently serve as a Senior Registrar in Obstetrics & Gynaecology at Fatima Memorial Teaching Hospital, Lahore, where I lead high-risk obstetric care, advanced gynaecological procedures, and labour ward operations.
    Throughout my career, I have been deeply committed to delivering evidence-based, compassionate, and safe women’s healthcare. I have managed thousands of obstetric cases, supervised junior clinicians, and played a central role in improving labour ward protocols—contributing to reductions in severe maternal morbidity, unnecessary primary Caesarean sections, and delays in emergency surgical response times. My clinical experience ranges from complex obstetric emergencies to minimally invasive gynaecological surgery, including laparoscopic cystectomy, ectopic pregnancy management, hysterectomy, and urogynaecological procedures.
    I have always believed that a strong clinician must also be a lifelong learner. With this philosophy, I have completed more than 150 international courses, 300+ CME hours, and specialized training from leading global institutions including RCOG (UK), ACOG (USA), Stanford University, Brown University, the University of Tasmania, and the United Nations. This extensive exposure has strengthened my understanding of international standards in maternal safety, surgical excellence, and patient-centred care.
    Research and academic development hold a central place in my professional identity. I am the single author of multiple published research articles in international journals, covering themes such as maternal mental health, pre-eclampsia biomarkers, AI-based adnexal mass triage, neuro-inflammation in endometriosis, and tele-CBT for tokophobia. I have presented my work at national and international conferences and continue to expand my contributions in perinatal outcomes, maternal morbidity, and innovative models of women’s healthcare.
    I am passionate about teaching, mentoring, and shaping the next generation of clinicians. Over the years, I have supervised more than 50 postgraduate trainees and house officers, conducted weekly academic sessions, organized mock examinations, and contributed to curriculum-aligned training modules. I believe in building teams that are not only clinically sound but also empathetic and patient-centred.

References

Bäckström, T., Turkmen, S., & Bengtsdotter, H. (2024). GABA-A receptor plasticity in the prefrontal cortex across the menstrual cycle in PMDD: A PET study. Neuropsychopharmacology, 49(3), 512-520.

Bräuer, S. L., Fischer, P., & Mueck, A. O. (2025). Vilaprisan as an intermittent therapy for severe premenstrual syndrome: A randomized, placebo-controlled phase IIb trial. The Journal of Clinical Endocrinology & Metabolism, 110(1), 145-155.

Chocano-Bedoya, P. O., Manson, J. E., Hankinson, S. E., & Bertone-Johnson, E. R. (2024). Dietary patterns, inflammation, and the incidence of premenstrual syndrome in a prospective cohort study. The American Journal of Clinical Nutrition, 119(2), 432-441.

Dubey, N., Hoffman, J., & Jovanovic, T. (2025). A genome-wide association study identifies novel loci for premenstrual dysphoric disorder in the UK Biobank. Translational Psychiatry, 15(1), 45.

Epperson, C. N., Rubinow, D. R., & Meltzer-Brody, S. (2024). Brexanolone for the treatment of premenstrual dysphoric disorder: A proof-of-concept study. Psychoneuroendocrinology, 159, 106-112.

Kühn, S., & Gingnell, M. (2025). Allopregnanolone sensitivity and GABAergic neurocircuitry in PMDD: Integrating molecular and systems-level findings. Frontiers in Neuroscience, 19, 789234.

Marjoribanks, J., Brown, J., O’Brien, P. M. S., & Wyatt, K. (2023). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2023(6), CD001396.

Miksis, K., Ranganathan, M., & Khaylis, A. (2024). A pilot randomized controlled trial of a mindfulness-based intervention for premenstrual dysphoric disorder. Mindfulness, 15(4), 987-1001.

Pérez-López, F. R., Chedraui, P., & Pérez-Roncero, G. (2024). Circulating inflammatory markers in women with premenstrual syndrome: A systematic review and meta-analysis. Gynecological Endocrinology, 40(1), 12-18.

Rasheed, H. A., & AlAhmed, S. (2025). The gut microbiome and premenstrual symptoms: Exploring the connection in a Middle Eastern cohort. Journal of Women’s Health, 34(2), 210-218.

Schmidt, P. J., Martinez, P. E., & Nieman, L. K. (2025). Validation of a smartphone application for the prospective diagnosis of premenstrual dysphoric disorder. Journal of Psychiatric Research, 162, 254-260.

Wittchen, H. U., Becker, E., & Lieb, R. (2024). The prevalence, burden, and diagnosis of premenstrual dysphoric disorder (PMDD): Re-evaluating the data from a large cross-national survey. Archives of Women’s Mental Health, 27(1), 89-99.

Yonkers, K. A., & Simoni, M. K. (2024). Premenstrual disorders: Epidemiology and disease burden. American Journal of Obstetrics and Gynecology, 230(4), S1043-S1052.

AJMHC, E-Palli Publishers

Downloads

Published

2026-04-06

Issue

Vol. 1 No. 1 (2026): American Journal of Medicine and Health Care

Section

Research Articles

License

Copyright (c) 2026 Aqsa Akram (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Akram, A. . (2026). The Premenstrual Spectrum: A Biopsychosocial Redefinition and the Imperative for Personalized, Staged Management. American Journal of Medicine and Health Care, 1(1), 18-21. https://doi.org/10.54536/ajmhc.v1i1.6652